[Federal Register Volume 60, Number 48 (Monday, March 13, 1995)]
[Notices]
[Page 13438]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 95-6127]
=======================================================================
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Food and Drug Administration
[Docket No. 95N-0059]
Drug Export; Abbott HTLV-I/HTLV-II EIA
AGENCY: Food and Drug Administration, HHS.
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: The Food and Drug Administration (FDA) is announcing that
Abbott Laboratories, Inc., has filed an application requesting approval
for the export of the human biological product HTLV-I/HTLV-II EIA to
Australia, Austria, Belgium, Denmark, Federal Republic of Germany,
Finland, France, Iceland, Ireland, Italy, Luxembourg, The Netherlands,
New Zealand, Norway, Portugal, Sweden, Switzerland, and The United
Kingdom.
ADDRESSES: Relevant information on this application may be directed to
the Dockets Management Branch (HFA-305), Food and Drug Administration,
rm. 1-23, 12420 Parklawn Dr., Rockville, MD 20857, and to the contact
person identified below. Any future inquiries concerning the export of
human biological products under the Drug Export Amendments Act of 1986
should also be directed to the contact person.
FOR FURTHER INFORMATION CONTACT: Frederick W. Blumenschein, Center for
Biologics Evaluation and Research (HFM-660), Food and Drug
Administration, 1401 Rockville Pike, Rockville, MD 20852-1448, 301-594-
1070.
SUPPLEMENTARY INFORMATION: The drug export provisions in section 802 of
the Federal Food, Drug, and Cosmetic Act (the act) (21 U.S.C. 382)
provide that FDA may approve applications for the export of human
biological products that are not currently approved in the United
States. Section 802(b)(3)(B) of the act sets forth the requirements
that must be met in an application for approval. Section 802(b)(3)(C)
of the act requires that the agency review the application within 30
days of its filing to determine whether the requirements of section
802(b)(3)(B) have been satisfied. Section 802(b)(3)(A) of the act
requires that the agency publish a notice in the Federal Register
within 10 days of the filing of an application for export to facilitate
public participation in its review of the application. To meet this
requirement, the agency is providing notice that Abbott Laboratories,
Inc., One Abbott Park Rd., Abbott Park, IL 60064, has filed an
application requesting approval for the export of the human biological
product Abbott HTLV-I/HTLV-II EIA to Australia, Austria, Belgium,
Denmark, Federal Republic of Germany, Finland, France, Iceland,
Ireland, Italy, Luxembourg, The Netherlands, New Zealand, Norway,
Portugal, Sweden, Switzerland, and The United Kingdom. The test is
intended as a screen for donated blood to prevent transmission of HTLV-
I and HTLV-II to recipients of cellular blood products and as an aid in
the clinical diagnosis of HTLV-I and HTLV-II related diseases. The
application was received and filed in the Center for Biologics
Evaluation and Research on January 9, 1995, which shall be considered
the filing date for purposes of the act.
Interested persons may submit relevant information on the
application to the Dockets Management Branch (address above) in two
copies (except that individuals may submit single copies) and
identified with the docket number found in brackets in the heading of
this document. These submissions may be seen in the Dockets Management
Branch between 9 a.m. and 4 p.m., Monday through Friday.
The agency encourages any person who submits relevant information
on the application to do so by March 23, 1995, and to provide an
additional copy of the submission directly to the contact person
identified above, to facilitate consideration of the information during
the 30-day review period.
This notice is issued under the Federal Food, Drug, and Cosmetic
Act (sec. 802 (21 U.S.C. 382)) and under authority delegated to the
Commissioner of Food and Drugs (21 CFR 5.10) and redelegated to the
Center for Biologics Evaluation and Research (21 CFR 5.44).
Dated: February 28, 1995.
James C. Simmons,
Acting Director, Office of Compliance, Center for Biologics Evaluation
and Research.
[FR Doc. 95-6127 Filed 3-10-95; 8:45 am]
BILLING CODE 4160-01-F
